Skip to main content

Brovana FDA Approval History

FDA Approved: Yes (First approved October 6, 2006)
Brand name: Brovana
Generic name: arformoterol tartrate
Dosage form: Inhalation Solution
Company: Sepracor Inc.
Treatment for: COPD

Brovana (arformoterol tartrate) is a long-acting beta2-agonist for inhalation via a nebulizer, used for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Development timeline for Brovana

DateArticle
Oct  6, 2006Approval Brovana Sepracor Inc. - Treatment for Chronic Obstructive Pulmonary Disease
Feb 13, 2006Sepracor's Arformoterol NDA Filed by FDA; Drug Candidate for Chronic Obstructive Pulmonary Disease Moves Into Formal Review
Dec 13, 2005Sepracor Announces Submission of Arformoterol NDA to FDA for Chronic Obstructive Pulmonary Disease

See also

Brovana (arformoterol tartrate) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer